Hematocrit: How to Read It

Hematocrit measures the percentage of total blood volume that is made up of red blood cells, as opposed to plasma and other components. It is one of the most basic and most frequently ordered blood values, typically reported as part of a complete blood count (CBC), and it takes on particular relevance in a hormone-optimization context because testosterone can influence red blood cell production.

For how hematocrit fits alongside the hormone-specific markers on this site, start with the guide to reading a hormone panel.

What hematocrit measures

Blood is made up of red blood cells, white blood cells, platelets, and plasma (the liquid component). Hematocrit isolates just the red blood cell fraction and reports it as a percentage of total blood volume. Because red blood cells carry oxygen throughout the body, hematocrit is most commonly used as a screening tool for anemia (too few red blood cells) on the low end and polycythemia or erythrocytosis (too many) on the high end.

Hematocrit is ordered as routine screening, as part of a general wellness check, or specifically to monitor a known condition or treatment. In the context of testosterone therapy, it's monitored because testosterone is understood to stimulate red blood cell production — through several proposed mechanisms including effects on erythropoietin and iron regulation — which can raise hematocrit over the course of treatment.

Reference ranges, and why they vary

According to MedlinePlus, one commonly cited normal hematocrit range is approximately 37% to 48% for men and approximately 34% to 43% for women, with different expected ranges for newborns and infants. MedlinePlus itself notes that normal hematocrit varies by sex, age, smoking status, and altitude of residence — a genuinely wide set of variables — and explicitly recommends asking your own provider what your hematocrit level should be rather than relying on a single universal figure.

Reference ranges also differ modestly across laboratories depending on the analyzer and method used, so as with every marker on this site, the range printed on an individual lab report is the one that applies to that specific result.

What commonly drives hematocrit up or down

In general physiological terms, low hematocrit (a marker of possible anemia) is commonly associated with recent or chronic blood loss, nutritional deficiencies such as low iron, B12, or folate, bone marrow disorders, chronic kidney disease, and conditions that destroy red blood cells faster than they can be replaced.

High hematocrit is commonly associated with dehydration (which concentrates the existing red blood cells in a smaller plasma volume), living at high altitude, certain lung and heart conditions that trigger the body to produce more red blood cells to compensate for lower blood oxygen, bone marrow disorders such as polycythemia vera, and — relevant to this site's context — testosterone therapy. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy identifies erythrocytosis, defined there as hematocrit above 54%, as the most frequently observed adverse finding in testosterone trials, and states that clinicians should not start testosterone therapy in men whose baseline hematocrit already exceeds their lab's upper limit of normal. This is general clinical background, not guidance for any individual reader — what a specific hematocrit result means, and what if anything should be done about it, is a determination for a licensed physician.

Why trends matter more than a single snapshot

Hematocrit can shift with short-term factors like hydration status at the time of the blood draw, recent altitude exposure, and even something as simple as whether someone drank enough water that morning. A single hematocrit reading taken under unusual conditions may not reflect someone's typical baseline.

This is part of why physicians monitoring testosterone therapy don't rely on one hematocrit value — the Endocrine Society guideline calls for a baseline check before starting therapy and periodic reassessment afterward, building a trend line over time rather than reacting to any single number. A hematocrit that rises gradually and levels off tells a different story than one that spikes sharply, and only a physician reviewing the full trend alongside the rest of a patient's labs and history can determine what that pattern means and whether any adjustment is warranted.

Why hematocrit gets particular attention in a hormone-optimization context

Hematocrit sits in a slightly different category from the other markers covered on this site. Where testosterone, estradiol, SHBG, and IGF-1 are all direct measures of the endocrine system itself, hematocrit is a downstream effect — a marker that can move as a secondary consequence of a hormone therapy rather than a hormone being measured directly. That distinction is exactly why it's monitored on its own schedule alongside the hormone panel rather than folded into it: a stable, well-managed testosterone level can still coincide with a hematocrit that's trending upward, and the two pieces of information answer different questions.

It's also a marker where the safety literature is comparatively concrete. Unlike some of the interpretive nuance involved in reading testosterone or estradiol, the Endocrine Society guideline draws an explicit numeric line — hematocrit above 54% — that defines erythrocytosis in the context of testosterone therapy, along with a specific recommendation against initiating therapy above that threshold at baseline. Even so, the same guideline is candid that the hematocrit level at which downstream cardiovascular or clotting risk actually increases is not established with precision, which is exactly the kind of open clinical question that belongs to an individual's physician to weigh, not a general educational page.

The testosterone replacement therapy education page covers the broader treatment context in which hematocrit monitoring typically comes up. As always, interpretation of a specific hematocrit result belongs to a licensed physician, not a general reference article.